David D. Allison - 08 Apr 2022 Form 4/A - Amendment Insider Report for CinCor Pharma, Inc.

Role
Director
Signature
/s/ Cathy Rude, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
08 Apr 2022
Net transactions value
+$12,498
Form type
4/A - Amendment
Filing time
20 Jul 2022, 16:39:45 UTC
Date Of Original Report
11 May 2022
Previous filing
06 Jan 2022
Next filing
17 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CINC Stock Option (Right to Buy) Award $12,498 +1,038 $12.04 1,038 08 Apr 2022 Common Stock 1,038 $19.55 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of retainer fees of $12,500.
F2 This amendment to the Form 4 initially filed on May 11, 2022 is being made to clarify the purpose of the option grant set forth in footnote 1 above and the amount in director retainer fees foregone as set forth in box 8 above.